RBS-001 not checked

Rophibio, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye”In the company’s words, NCT06470373 on ClinicalTrials.gov
Tested for
Neovascular Age-related Macular Degeneration (nAMD)
Main trialPhase 3
“This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related macular degeneration.”In the company’s words, NCT06470373 on ClinicalTrials.gov
Copy of
Eylea (Regeneron Pharmaceuticals)Tested side by side with the original in NCT06470373

Other drugs for Neovascular Age-related Macular Degeneration (nAMD)

All 56 drugs for Neovascular Age-related Macular Degeneration (nAMD)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Sep 2026 A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow RBS-001

Following is part of Solo: you see every change to RBS-001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in